Recent News

• 02.06.2025 - Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
• 01.13.2025 - Immunovant Announces $450 Million Private Placement

Recent Filings

• 02.06.2025 - 8-K Current report
• 02.06.2025 - EX-99.1 EX-99.1
• 02.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.21.2025 - D Notice of Exempt Offering of Securities
• 01.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership